Eunice S. Wang MD
Staff Physician
Leukemia Service, Department of Medicine

Research Assistant Professor, Leukemia Service
Departments of Medicine and Immunology
Roswell Park Cancer Institute
Phone: (716) 845-3544
Fax: (716) 845-8446
Eunice.Wang@roswellpark.org

Current Program

•  role of angiogenesis in promoting the growth of hematological malignancies
• screening anti-angiogenic and other biological agents for effects on clinically relevant human leukemia in vivo
• early stage clinical trials for acute leukemia

Profile

Dr. Eunice Wang joined the faculty of Roswell Park Cancer Institute in 2003 and was appointed to the Leukemia Section of the Department of Medicine. She earned her medical degree from the Keck-University of Southern California School of Medicine and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed clinical hematology-oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, New York.

Dr Wang is licensed in New York State and is certified by the American Board of Internal Medicine (Internal Medicine 1999; Medical Oncology, 2003). She also is a Research Assistant Professor, School of Medicine & Biomedical Sciences, University of Buffalo. She is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and American Society of Hematology.

Dr. Wang has authored or co-authored several journal articles, abstracts and book chapters. In addition to her clinical practice, she maintains an active translational laboratory research program into the role of angiogenesis and telomerase in the hematological malignancies.

Key Publications

1. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MAS. Targeting autocrine and paracrine VEGF receptor pathways regresses human lymphoma xenografts in vivo (manuscript under revision).
2. Budak-Alpdogan, Alpdogan O, Banarjee D, Wang ES, Moore MAS, Bertino JR. Post-transplant methotrexate and cytarabine inhibits progression of human diffuse large cell lymphoma in NOD-SCID mice transplanted with double mutant dihydrofolate reductase and cytidine deaminase fusion gene transduced bone marrow (Submitted).
3. Wang ES, Wu K, Chin A, Chen-Kiang S, Gryaznov S, Moore MAS. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103 (1): 258-266, 2004 (Published Blood online Sept 11, 2003).
4. Wang ES, O'Connor OA, She Y, Zelenetz A, Sirotnak FM, Moore MAS. Activity of a novel anti-folate (PDX, 10 propargyl 10-deaza-aminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44 (6): 1027-1035, 2003.